Detection of drug-induced, superoxide-mediated cell damage and its prevention by antioxidants.
The mode of the cytotoxic activity of three benzo(c)fluorene derivatives was characterized. The observed morphological changes of lysosomes or variations of mitochondrial activity are assumed to be the consequence of cell protection against oxidative damage and/or the part of the damage process. To establish the relationship between the quantity of superoxide (O2*-) generated and the degree of damage resulting from O2*-, a simple system based on measurement of 3-(4-iodophenyl)-2-(4-nitrophenyl)-5-phenyltetrazolium chloride (INT) reductase activity in the presence of superoxide dismutase (SOD) was used. The functionality of the chosen battery of in vitro tests was proved using several known superoxide inducers: cyclosporin A (CsA) and benzo(a)pyrene (BP), as well as noninducers: citrinin (CT) and cycloheximide (CH). From the results followed that the cell growth tests are much better indices of toxicity than the other tests. The model system for the evaluation of the protective capacity of antioxidants against superoxide-induced cytotoxicity included simultaneous exposure of HeLa cells to cytotoxic drugs and to quercetin (Qe), an antioxidant of plant origin. The complete abolishment of the inhibition of cell proliferation and clonogenic survival was concluded to be due to the protective effect of the antioxidant. These observations correlated with the decrease of superoxide content as estimated by the INT-reductase assay in the presence of SOD using the same model system, as well as with the increase of intracellular SOD content and its activity.
Horáková
K
K
Department of Biochemistry and Microbiology, Slovak University of Technology, Bratislava, Slovak Republic. horakova@chelin.chtf.stuba.sk
Sovcíková
A
A
Seemannová
Z
Z
Syrová
D
D
Busányová
K
K
Drobná
Z
Z
Ferencík
M
M
D000975:Antioxidants / Q000494:pharmacology*; D001564:Benzo(a)pyrene / Q000037:antagonists & inhibitors / Q000633:toxicity; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002953:Citrinin / Q000037:antagonists & inhibitors / Q000633:toxicity; D003124:Colorimetry; D003513:Cycloheximide / Q000037:antagonists & inhibitors / Q000633:toxicity; D016572:Cyclosporine / Q000037:antagonists & inhibitors / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D005449:Fluorenes / Q000037:antagonists & inhibitors / Q000633:toxicity; D005562:Formazans; D006367:HeLa Cells; D006801:Humans; D008247:Lysosomes / Q000187:drug effects / Q000378:metabolism; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D010088:Oxidoreductases / Q000378:metabolism; D011794:Quercetin / Q000031:analogs & derivatives* / Q000494:pharmacology; D013482:Superoxide Dismutase / Q000378:metabolism; D013481:Superoxides / Q000378:metabolism*; D013778:Tetrazolium Salts; D018675:Toxicity Tests; D015262:Xenobiotics / Q000037:antagonists & inhibitors* / Q000633:toxicity*
C405005:3,9-dimethoxybenfluron; D000975:Antioxidants; D005449:Fluorenes; D005562:Formazans; D013778:Tetrazolium Salts; D015262:Xenobiotics; D013481:Superoxides; C073746:9-hydroxybenfluron; C079782:MTT formazan; C012526:quercitrin; D001564:Benzo(a)pyrene; D002953:Citrinin; C034234:VUFB 13468; D016572:Cyclosporine; D003513:Cycloheximide; D011794:Quercetin; D010088:Oxidoreductases; D013482:Superoxide Dismutase